Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B

Young Kul Jung, Jong Eun Yeon, Woo Sik Han, Ji Hoon Kim, Jeong Han Kim, Jong Jae Park, Jae Seon Kim, Young Tae Bak, Wangdon Yoo, Sun Pyo Hong, Soo Ok Kim, So Young Kwon, Kwan Soo Byun, Chang Hong Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log 10 copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.

Original languageEnglish
Pages (from-to)212-218
Number of pages7
JournalGut and liver
Volume4
Issue number2
DOIs
Publication statusPublished - 2010 Jun

Keywords

  • Adefovir dipivoxil
  • Drug resistance
  • Virologic response

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B'. Together they form a unique fingerprint.

  • Cite this